- $3.14bn
- $1.88bn
- $630.20m
- 50
- 61
- 64
- 61
REG - Hutchmed China Ltd - Retirement of Independent Non-executive Directors
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Savolitinib SAVANNAH Phase II
AnnouncementRCS - Hutchmed China Ltd - Publication of Form 20-F
AnnouncementREG - Hutchmed China Ltd - 2024 Final Results and Business Updates
AnnouncementRCS - Hutchmed China Ltd - Phase II/III Study of Fruquintinib and Sintilimab
AnnouncementREG - Hutchmed China Ltd - Adoption of the 2025 Long Term Incentive Plan
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan
AnnouncementREG - Hutchmed China Ltd - Notice of Extraordinary General Meeting
AnnouncementRCS - Hutchmed China Ltd - Completed Enrollment of Phase II Study
AnnouncementREG - Hutchmed China Ltd - Directorate Change
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementREG - Hutchmed China Ltd - Notice of Results
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementRCS - Hutchmed China Ltd - Full Approval for ORPATHYS in China
AnnouncementRCS - Hutchmed China Ltd - China NDA Acceptance for ORPATHYS and TAGRISSO
AnnouncementREG - Hutchmed China Ltd - US$608m Divestment of Non-Core Joint Venture
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementREG - Hutchmed China Ltd - Appointment of Joint Corporate Broker
Announcement